John A Rossow1,2, Radhika Gharpure1,3, Julia Brennan1,4, Pryanka Relan1,3, Sabrina R Williams2, Snigdha Vallabhaneni2, Brendan R Jackson2, Caroline R Graber4,5,6, Sherry R Hillis5,7, William Schaffner7, John R Dunn4, Timothy F Jones4. 1. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. Waterborne Disease Prevention Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 4. Tennessee Department of Health, Nashville, Tennessee, USA. 5. Tennessee Emerging Infections Program, Nashville, Tennessee, USA. 6. Vanderbilt University School of Medicine, Department of Health Policy, Nashville, Tennessee, USA. 7. Vanderbilt University Medical Center, Nashville, Tennesse, USA.
Abstract
BACKGROUND: Injection drug use (IDU) is an established but uncommon risk factor for candidemia. Surveillance for candidemia is conducted in East Tennessee, an area heavily impacted by the opioid crisis and IDU. We evaluated IDU-associated candidemia to characterize the epidemiology and estimate the burden. METHODS: We assessed the proportion of candidemia cases related to IDU during January 1, 2014-September 30, 2018, estimated candidemia incidence in the overall population and among persons who inject drugs (PWID), and reviewed medical records to compare clinical features and outcomes among IDU-associated and non-IDU candidemia cases. RESULTS: The proportion of IDU-associated candidemia cases in East Tennessee increased from 6.1% in 2014 to 14.5% in 2018. Overall candidemia incidence in East Tennessee was 13.5/100 000, and incidence among PWID was 402-1895/100 000. Injection drug use-associated cases were younger (median age, 34.5 vs 60 years) and more frequently had endocarditis (39% vs 3%). All-cause 30-day mortality was 8% among IDU-associated cases versus 25% among non-IDU cases. CONCLUSIONS: A growing proportion of candidemia in East Tennessee is associated with IDU, posing an additional burden from the opioid crisis. The lower mortality among IDU-associated cases likely reflects in part the younger demographic; however, Candida endocarditis seen among approximately 40% underscores the seriousness of the infection and need for prevention. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Injection drug use (IDU) is an established but uncommon risk factor for candidemia. Surveillance for candidemia is conducted in East Tennessee, an area heavily impacted by the opioid crisis and IDU. We evaluated IDU-associated candidemia to characterize the epidemiology and estimate the burden. METHODS: We assessed the proportion of candidemia cases related to IDU during January 1, 2014-September 30, 2018, estimated candidemia incidence in the overall population and among persons who inject drugs (PWID), and reviewed medical records to compare clinical features and outcomes among IDU-associated and non-IDU candidemia cases. RESULTS: The proportion of IDU-associated candidemia cases in East Tennessee increased from 6.1% in 2014 to 14.5% in 2018. Overall candidemia incidence in East Tennessee was 13.5/100 000, and incidence among PWID was 402-1895/100 000. Injection drug use-associated cases were younger (median age, 34.5 vs 60 years) and more frequently had endocarditis (39% vs 3%). All-cause 30-day mortality was 8% among IDU-associated cases versus 25% among non-IDU cases. CONCLUSIONS: A growing proportion of candidemia in East Tennessee is associated with IDU, posing an additional burden from the opioid crisis. The lower mortality among IDU-associated cases likely reflects in part the younger demographic; however, Candida endocarditis seen among approximately 40% underscores the seriousness of the infection and need for prevention. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
candidemia; incidence; injection drug use
Authors: Sascha Dublin; Rod L Walker; Michael L Jackson; Jennifer C Nelson; Noel S Weiss; Michael Von Korff; Lisa A Jackson Journal: J Am Geriatr Soc Date: 2011-09-13 Impact factor: 5.562
Authors: J Bisbe; J M Miro; X Latorre; A Moreno; J Mallolas; J M Gatell; J P de la Bellacasa; E Soriano Journal: Clin Infect Dis Date: 1992-12 Impact factor: 9.079
Authors: Joji Suzuki; Jennifer Johnson; Mary Montgomery; Margaret Hayden; Christin Price Journal: Open Forum Infect Dis Date: 2018-08-07 Impact factor: 3.835
Authors: Ayesha Appa; Meredith Adamo; Stephenie Le; Jennifer Davis; Lisa Winston; Sarah B Doernberg; Henry Chambers; Marlene Martin; Nancy K Hills; Phillip O Coffin; Vivek Jain Journal: Clin Infect Dis Date: 2022-01-29 Impact factor: 9.079